Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.

Détails

ID Serval
serval:BIB_7B605F3478F7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
Périodique
Annals of Oncology
Auteur(s)
Colleoni M., Colleoni M., Gelber S., Simoncini E., Pagani O., Gelber R.D., Price K.N., Castiglione-Gertsch M., Coates A.S., Goldhirsch A.
Collaborateur(s)
International Breast Cancer Study Group
ISSN
0923-7534 (Print)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
2007
Volume
18
Numéro
7
Pages
1177-1184
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Résumé
BACKGROUND: The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome.
PATIENTS AND METHODS: From 1993 to 1999, IBCSG Trials 13-93 and 14-93 enrolled 2215 premenopausal and postmenopausal women with axillary node-positive, operable breast cancer. All patients received cyclophosphamide (Cytoxan, C) plus either doxorubicin (Adriamycin, A) or epirubicin (E) for four courses followed immediately (No Gap) or after a 16-week delay (Gap) by classical cyclophosphamide, methotrexate, and fluorouracil (CMF) for three courses. The median follow-up was 7.7 years.
RESULTS: The Gap and No-Gap groups had similar disease-free survival (DFS) and overall survival (OS). No identified subgroup showed a statistically significant difference, but exploratory subgroup analysis noted a trend towards decreased DFS for Gap compared with No Gap for women with estrogen receptor (ER)-negative tumors not receiving tamoxifen, especially evident during the first 2 years.
CONCLUSIONS: A 16-week gap between adjuvant AC/EC and CMF provided no benefit and may have increased early recurrence rates in patients with ER-negative tumors.
Mots-clé
Adult, Aged, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Breast Neoplasms/drug therapy, Breast Neoplasms/mortality, Chemotherapy, Adjuvant, Cyclophosphamide/administration & dosage, Disease-Free Survival, Doxorubicin/administration & dosage, Drug Administration Schedule, Epirubicin/administration & dosage, Female, Fluorouracil/administration & dosage, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis/pathology, Methotrexate/administration & dosage, Middle Aged, Neoplasm Recurrence, Local/epidemiology, Receptors, Estrogen/metabolism, Tamoxifen/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
08/10/2011 18:48
Dernière modification de la notice
08/05/2019 20:49
Données d'usage